Cyclic Peptides: Why the Chemistry That Works at the Bench Can Fail on Cost
Cyclisation and purification decisions made at milligram scale set the cost of goods at kilogram scale. By the time the candidate is chosen, the route is hard to change.
The industrial side of pharmaceutical outsourcing — capacity, chemistry, and the decisions behind them. Briefs from our analysis series, product updates, and featured CDMO partners.
Cyclisation and purification decisions made at milligram scale set the cost of goods at kilogram scale. By the time the candidate is chosen, the route is hard to change.
Peptide-based oncology programs use comparatively little API, but their manufacturing needs are exacting: small-scale GMP availability, specification control, analytical capability, inspection readiness, and a supply chain aligned to the patient.
Most peptide CDMO selection frameworks were written when capacity was available. They ask reasonable questions at the wrong level of specificity — and where qualified commercial capacity is scarce, that imprecision costs a place in the queue. Six recurring failure modes, and the evidence that settles each one.
Solid-phase peptide synthesis consumes around 13,000 kg of material for every kg of API — forty to eighty times a small molecule. As GLP-1-class demand pushes volumes the industry has never operated at, solvent supply, recovery, and disposal are becoming the binding constraint.
We tracked more than twenty peptide facility announcements from 2024 to 2026. Only a handful add commercial-scale API capacity — and in 2026, consolidation quietly shrank the field rather than widening it.
Two Phase 3 readouts have reset the ceiling for what peptide therapeutics can do. The more interesting story is everything the efficacy headline leaves out.